RT Journal Article
SR Electronic
T1 The genetic risk for COVID-19 severity is associated with defective innate immune responses
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.10.20229203
DO 10.1101/2020.11.10.20229203
A1 Kuijpers, Yunus
A1 Chu, Xiaojing
A1 Jaeger, Martin
A1 Moorlag, Simone J.C.F.M.
A1 Koeken, Valerie A.C.M.
A1 Zhang, Bowen
A1 de Nooijer, Aline
A1 Grondman, Inge
A1 Janssen, Nico
A1 Mourits, Vera P.
A1 J. de Bree, L. Charlotte
A1 de Mast, Quirijn
A1 van de Veerdonk, Frank L.
A1 Joosten, Leo A.B.
A1 Li, Yang
A1 Netea, Mihai G.
A1 Xu, Cheng-Jian
YR 2021
UL http://medrxiv.org/content/early/2021/05/14/2020.11.10.20229203.abstract
AB Recent genome-wide association studies (GWASs) of COVID-19 patients of European ancestry have identified genetic loci significantly associated with disease severity (1). Here, we employed the detailed clinical, immunological and multi-omics dataset of the Human Functional Genomics Projects (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19. A genomics investigation intersected with functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with increased susceptibility for severe disease in individuals with defective monocyte-derived cytokine production; ii. genetic susceptibility related to ABO blood groups is probably mediated through the von Willebrand factor (VWF) and endothelial dysfunction. We further validated these identified associations at transcript and protein levels by using independent disease cohorts. These insights allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy.One Sentence summary In this study, we explore the physiological significance of the genetic variants associated with COVID-19 severity using detailed clinical, immunological and multi-omics data from large cohorts. Our findings allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMGN was supported by an ERC Advanced Grant (833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research. YL was supported by an ERC starting Grant (948207) and a Radboud University Medical Centre Hypatia Grant (2018). CJX was supported by Helmholtz Initiative and Networking Fund (1800167).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The 300BCG (NL58553.091.16) and 500FG (NL42561.091.12) studies were approved by the Arnhem-Nijmegen Medical Ethical Committee. Experiments were conducted according to the principles expressed in the Declaration of Helsinki. Samples of venous blood were drawn after informed consent was obtained. The COVID-19 Single cell RNA sequencing study is approved by the Institutional Review board of Charite (EA2/066/20). Written informed consent was provided by all patients or legal representatives for participation in the study. This COVID-19 protemics study was performed according the latest version of the declaration of Helskini and guidelines for good clinical practice. The Arnhem-Nijmegen Medical Ethical Committee approved the study protocol (CMO 2020-6344 and CMO 2016-2923). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes500FG data used in this project have been archived in the BBMRI-NL data infrastructure (https://hfgp.bbmri.nl/). This allows flexible data querying and download, including sufficiently rich metadata and interfaces for machine processing and using FAIR principles to optimize Findability, Accessibility, Interoperability and Reusability.